抑制 ангиотензин转化酶对慢性腹腔内血瘤的复发和内部结构的影响
Michael Veldeman1, Hani Ridwan2, Mohamed Alzaiyani1
1Department of Neurosurgery, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, Germany.
Journal of clinical medicine
|August 29, 2024
概括
常用于心血管疾病的 ангиотензин转化酶 (ACE) 抑制剂被发现与慢性腹腔内血瘤 (cSDH) 复发的两倍增加有关. 这一发现突出了使用ACE抑制剂的患者中cSDH复发的潜在风险因素.
科学领域:
- 神经外科 神经外科
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于人口老龄化和抗血栓药物使用增加,慢性腹腔内血瘤 (cSDH) 越来越令人担忧.
- 关于血管酶转化酶 (ACE) 抑制剂是否影响cSDH复发率的现有研究是相互矛盾的.
- 这项研究调查了ACE抑制剂是否通过影响血液瘤膜形成来影响cSDH复发.
研究的目的:
- 评估手术前使用ACE抑制剂与慢性腹腔内血瘤 (cSDH) 复发率之间的关联.
- 为了确定ACE抑制剂是否独立预测cSDH复发,考虑到血液瘤结构和抗血栓药物使用.
主要方法:
- 在2015年至2020年期间,对398名接受cSDH手术的患者进行了回顾性分析.
- 根据CT成像特征将血瘤分为八个亚型.
- 病人的手术前药物治疗的文档,特别确定使用ACE抑制剂.
主要成果:
- 142名患者 (35.9%) 在入院前服用ACE抑制剂;拉米普利是最常见的.
- 服用ACE抑制剂的患者同时使用抗血栓药物的比率更高 (63.4%与42.6%相比).
- 手术前使用ACE抑制剂独立地与cSDH复发的两倍增加有关 (OR2.026,95%CI1.214至3.384;p=0.007).
结论:
- 在手术前使用ACE抑制剂显着与慢性腹腔内血瘤复发的可能性增加有关.
- 即使调整了血液瘤架构,手术类型和抗血栓药物治疗后,这种关联仍然很重要.
- 这些发现表明ACE抑制剂在cSDH复发中的潜在作用,需要进一步调查.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
511
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
511
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
510
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
510
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
142
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
142